US Patent

US10487061 — Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof

Method of Use · Assigned to Chimerix Inc · Expires 2034-10-10 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of synthesis for phosphonate ester compounds, including those with high purity and stability, and their morphic forms.

USPTO Abstract

The disclosure describes methods of synthesis of phosphonate ester compounds. The methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity and stability. Also disclosed are morphic forms of phosphonate ester compounds.

Drugs covered by this patent

Tembexa (BRINCIDOFOVIR) · Emergent Biodefense

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3165`	—	Tembexa

Patent Metadata

Patent number: US10487061
Jurisdiction: US
Classification: Method of Use
Expires: 2034-10-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Chimerix Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.